Limits of predictive models using microarray data for breast cancer clinical treatment outcome.
about
Genetic instability in the tumor microenvironment: a new look at an old neighborPredictive and prognostic molecular markers for cancer medicinePathways to tamoxifen resistance.Prioritizing genes associated with prostate cancer developmentMistakes in validating the accuracy of a prediction classifier in high-dimensional but small-sample microarray data.Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.DATE analysis: A general theory of biological change applied to microarray data.Does applicability domain exist in microarray-based genomic research?HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling.A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer.The use of microarray technologies in clinical oncologyEpigenetics of prostate cancer: beyond DNA methylationHigh expression of Talin-1 is associated with poor prognosis in patients with nasopharyngeal carcinoma.Early developments in gene-expression profiling of breast tumors: potential for increasing black-white patient disparities in breast cancer outcomes?Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistanceSelecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer.Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy.Evaluation of HOXB13 as a molecular marker of recurrent prostate cancerUrinary Nucleic Acid TSPAN13-to-S100A9 Ratio as a Diagnostic Marker in Prostate Cancer.Statistical challenges with gene expression studies.A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy.In silico discovery of mitosis regulation networks associated with early distant metastases in estrogen receptor positive breast cancers.Gene-expression signatures in oncology diagnostics.An expression signature of estrogen-regulated genes predicts disease-free survival in tamoxifen-treated patients better than progesterone receptor status.Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management.Molecular subtypes in breast cancer evaluation and management: divide and conquer.MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment.Genome signatures, self-organizing maps and higher order phylogenies: a parametric analysisImproving Pathological Assessment of Breast Cancer by Employing Array-Based Transcriptome Analysis.Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?Genomic predictors of outcome and treatment response in breast cancer.Making the case for molecular staging of malignant pleural mesothelioma.An overview of the molecular pathology of head and neck cancer, and its clinical implications.Molecular classification of breast carcinomas with particular emphasis on "basal-like" carcinoma: a critical review.Two-gene expression ratio as predictor for breast cancer treated with tamoxifen: evidence from meta-analysis.Gene-Expression-Based Predictors for Breast Cancer.High-Dimensional Profiling for Computational Diagnosis.MetaKTSP: a meta-analytic top scoring pair method for robust cross-study validation of omics prediction analysis.HOXB9 Expression Correlates with Histological Grade and Prognosis in LSCC.
P2860
Q26801374-E660E94C-72D3-448E-9594-7F214472F6B2Q28743108-671BB8F6-F084-40DD-9FD2-8B66764B271AQ30441001-97135170-C964-4477-8280-FB8CC992469FQ30497425-CADACF96-6979-4DB7-B883-4B8E0755A3CBQ31151025-604BB24C-DDEA-408C-9A8C-FB73552BD6BEQ33337206-ADE64F12-C7E3-41A0-B7E4-EAAD8FC21F23Q33494114-84BF695E-6C8F-4F5F-941F-C9015E9A42B2Q33604686-B597DED7-2D0D-434E-8924-841AE12E82C0Q33933887-5AEBC5FC-7850-4079-96D3-337464DDCD9DQ34029272-D1293B55-D0D9-47F4-B990-880E9ACA32AFQ34496896-5A78CC40-519D-47D3-8610-A567FAFD05BCQ34505232-9F06DD78-B40E-4A6D-9A06-8663035EB877Q35583857-C0A4F3F5-019C-414C-BF04-BCB5A91AD185Q35622059-881AB254-998B-4B41-A542-4F26BDEC5AADQ35795153-9739E684-FCF0-4D73-A708-557F9AA5AFF8Q36054860-FB867129-FAA0-4E58-A825-B9017C4962C1Q36117673-11C07993-7240-4B38-BBAD-61A1BDDCB35EQ36230602-860E5FFA-5824-4349-B150-A5862125540BQ36383272-47394FF0-F281-4B82-938C-2348B8A0C039Q36400527-64494C42-B4AE-455D-9FF8-1DDA7AE90131Q36446875-1734C9B0-39D8-4459-BDEA-767D1BDED922Q36609946-986500EF-2787-4995-9CED-B303B546DC51Q36629870-F812C35F-A282-4E56-A706-B84061C73C85Q36690245-320E68CB-AAB5-459F-AC12-4B289C7CBB2FQ36742417-3DD363D5-63B1-4CB5-818C-F9CD8B4F1694Q36816034-76AE157B-5A1F-49E2-8DEF-0FE54E2330E7Q37052739-D1AB7ED7-2C71-44E8-B541-8CDD39DDAF7CQ37130478-949FDDFD-F9CA-488C-A5BB-121DDE8C2B4CQ37197254-9F59E3E8-90CC-4E1B-83A3-E8A7A87B2C62Q37214212-12C3E4DD-507C-4494-867C-02711F12A374Q37356684-84E56BDD-2B85-4AAE-BF6F-E35883BEB8A5Q37523889-BC732317-AD36-4647-A919-B4F36DEBFA97Q37613240-10FB33BC-64C4-4014-B28A-109AE8C0B389Q37903910-3A914EE7-3EB9-48F5-94CF-0E97189D77F8Q37974614-8B7F246C-0A59-47B7-A36B-11E2DC92BE36Q38165072-869AD06D-537E-4C9A-AB3D-8833DF2A6B8DQ38555220-0F01EDE1-80F9-4B2C-AE17-4F83457802E0Q39023264-AAF7DA94-090E-4A43-B7A7-A4246A10C32AQ39788006-DC22796D-4B07-4BB4-9750-36F6B95B3398Q41229470-C1C541CB-064F-46E3-A0E2-D3B126D7687F
P2860
Limits of predictive models using microarray data for breast cancer clinical treatment outcome.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Limits of predictive models us ...... er clinical treatment outcome.
@ast
Limits of predictive models us ...... er clinical treatment outcome.
@en
type
label
Limits of predictive models us ...... er clinical treatment outcome.
@ast
Limits of predictive models us ...... er clinical treatment outcome.
@en
prefLabel
Limits of predictive models us ...... er clinical treatment outcome.
@ast
Limits of predictive models us ...... er clinical treatment outcome.
@en
P2860
P50
P356
P1476
Limits of predictive models us ...... er clinical treatment outcome.
@en
P2093
Danila Coradini
James F Reid
P2860
P304
P356
10.1093/JNCI/DJI153
P407
P577
2005-06-01T00:00:00Z